What are appropriate augmentation or switching strategies for a patient with treatment‑resistant major depressive disorder currently taking fluoxetine 60 mg daily and bupropion 450 mg daily?

Treatment-Resistant Depression on Fluoxetine 60mg and Bupropion 450mg

For a patient with treatment-resistant depression already on maximally-dosed fluoxetine and bupropion, the most evidence-based next step is augmentation with cognitive behavioral therapy (CBT), or if pharmacologic augmentation is preferred, consider aripiprazole or quetiapine as these have the strongest evidence for efficacy in this scenario.

Current Clinical Situation

You have a patient on two maximally-dosed second-generation antidepressants (SGAs) from different classes—an SSRI (fluoxetine 60mg) and a norepinephrine-dopamine reuptake inhibitor (bupropion 450mg, which is the maximum FDA-approved dose) 1, 2. This represents treatment resistance, as the patient has failed adequate trials of two different antidepressant classes.

Evidence-Based Next Steps

Primary Recommendation: Augmentation Strategy

The 2016 American College of Physicians guidelines specifically address your situation 3. When patients fail initial SGA treatment, the evidence shows:

• Augmenting with another SGA: Low-quality evidence showed no difference in response or remission when augmenting citalopram with bupropion versus buspirone, though bupropion decreased depression severity more than buspirone 3

• Augmenting with cognitive therapy: Low-quality evidence showed no difference in response, remission, or depression severity between augmenting with another SGA (bupropion or buspirone) versus augmenting with cognitive therapy 3

However, since your patient is already on bupropion, adding another SGA is not the optimal choice.

Specific Augmentation Options

1. Atypical Antipsychotics (Strongest Evidence)

Aripiprazole and quetiapine have the most robust evidence for augmentation in treatment-resistant depression 4:

• Aripiprazole: 5 positive double-blind controlled trials out of 5, with FDA indication for TRD. OR = 1.85 (95% CrI, 1.27-2.27) versus placebo 4
• Quetiapine: 3 positive trials out of 3, with FDA indication for TRD. OR = 1.92 (95% CrI, 1.39-3.13) versus placebo 4

Important caveat: Both have significantly higher discontinuation rates due to side effects compared to placebo. Quetiapine (OR = 3.85) and aripiprazole (OR = 2.51) were less well tolerated than placebo 4. Monitor for metabolic syndrome, weight gain, sedation, and extrapyramidal symptoms.

2. Lithium Augmentation

Lithium showed efficacy (OR = 1.56; 95% CrI, 1.05-2.55) but with less robust evidence than aripiprazole or quetiapine 4. Traditional evidence supports lithium augmentation of TCAs, but evidence for SSRI augmentation is conflicting (1 positive trial out of 4) 5. However, lithium is particularly valuable if the patient has:

• Suicidal ideation
• Any bipolar spectrum features
• History suggesting bipolar depression 5, 6

Monitoring requirements: Thyroid function, renal function, and lithium levels are mandatory.

3. Cognitive Behavioral Therapy

CBT augmentation has moderate-quality evidence showing equivalence to pharmacologic augmentation 3. This is the safest option with no medication-related adverse effects. The 2016 ACP guidelines show that augmenting current antidepressants with CBT produces similar response and remission rates as adding another medication 3.

Alternative: Switching Strategy

If augmentation fails or is not tolerated, switching to a different antidepressant class is supported by moderate-quality evidence 3:

• Switching from one SGA to another (bupropion vs. sertraline vs. venlafaxine) showed no significant differences in response or remission 3
• Venlafaxine (SNRI) would be a logical switch given the patient has tried an SSRI and bupropion 5
• Consider a TCA if tolerated, as switching from SSRI to TCA showed positive results (2 positive trials out of 3) 5

Emerging Options for Severe TRD

Ketamine/Esketamine

The 2022 VA/DoD guidelines now recommend ketamine or esketamine for patients who have failed multiple adequate pharmacologic trials 7:

• Intranasal esketamine improved depressive symptoms in patients with TRD who failed at least 2 previous adequate antidepressant trials 7
• Ketamine infusions showed significant improvement in depressive symptoms persisting up to 7 days when added to ongoing antidepressant treatment 7

Critical limitations:

• Reserved for patients who have failed multiple therapies (your patient qualifies)
• Esketamine requires REMS certification and 2-hour post-treatment monitoring 7
• Long-term efficacy and safety data are limited 7

Practical Clinical Algorithm

Step 1: Verify adequate trial duration (6-8 weeks at current doses) and medication adherence 8

Step 2: Screen for hidden bipolarity—subsyndromal bipolar features are a common cause of treatment resistance 6. If present, prioritize lithium or mood stabilizers over additional antidepressants.

Step 3: Choose augmentation strategy based on:

• If patient prefers non-pharmacologic: Add CBT (equivalent efficacy, no medication side effects) 3

• If rapid response needed or severe symptoms: Consider aripiprazole (start 2-5mg daily) or quetiapine (start 50mg at bedtime, titrate to 150-300mg) 4

• If suicidal ideation or bipolar features: Consider lithium augmentation (start 300mg, titrate to therapeutic level 0.6-1.0 mEq/L) 4, 5

Step 4: If augmentation fails after adequate trial (4-6 weeks), consider:

• Switching to venlafaxine or TCA 5
• Referral for ketamine/esketamine if multiple strategies have failed 7

Critical Monitoring Points

• Bupropion is already at maximum dose (450mg/day) 1. Do not increase further due to seizure risk.
• Monitor blood pressure with current regimen, as both fluoxetine and bupropion can increase BP 1
• Screen for activation/mania when adding any augmentation agent 1
• Reassess within 1-2 weeks of any medication change for worsening depression or suicidality 8

Common Pitfalls to Avoid

1. Don't add another antidepressant without considering atypical antipsychotics first—the evidence is stronger for aripiprazole/quetiapine augmentation 4

2. Don't assume treatment resistance without ruling out pseudo-resistance: medication non-adherence, inadequate dosing, insufficient trial duration, or unrecognized bipolar disorder 6

3. Don't switch antidepressants prematurely—augmentation may be more effective than switching at this stage 3

4. Don't overlook CBT—it has equivalent efficacy to pharmacologic augmentation with better tolerability 3